LAKEWOOD, Colo.—May 26, 2011— Terumo Corporation announced today the appointment of Mr. David Perez as Chairman of the Global Blood Management business, representing the combined businesses of Terumo Transfusion and CaridianBCT, as of May 20, 2011, to succeed to Mr. Koji Nakao. Mr. Perez will also continue in his role as President and CEO of the combined Terumo Transfusion and CaridianBCT businesses. The global headquarters will remain located in Colorado, U.S.
Mr. Koji Nakao was recently appointed to Representative Director and Chairman of the Terumo Corporation Board on May 11, 2011.
As Chairman of the third largest business within Terumo, Mr. Perez will have an essential role in the 10-year growth strategy for Terumo Corporation. "We expect the Global Blood Management business will contribute significantly to the growth of the whole Terumo organization," stated Mr. Yutaro Shintaku, President of Terumo Corporation. Mr. Shintaku will become a new director on the Global Blood Management business board.
"Establishing the new chairman and the new director affirms the importance of the Global Blood Management business and the integration of the Terumo Transfusion and CaridianBCT businesses ," said Mr. Nakao. "This integration is not only important to Terumo, but also to me personally because of my involvement and relationships. I will assist Mr. Perez and our associates in any way possible."
" It is my privilege and honor to serve as the Chairman of the Global Blood Management business board, and I am excited to bring the value of the combined businesses to our associates, customers and the patients we ultimately serve," said Mr. Perez.
On April 13, 2011, Terumo Corporation completed the acquisition of CaridianBCT as a part of the core strategy to achieve the long-term growth target revenue of ¥1 trillion by the year 2020. The acquisition positions Terumo's new Global Blood Management business as the global leader in the blood bank technology industry, with revenues in excess of $830 million. The combined organization will be able to offer blood bank customers a wider range of blood processing technologies as well as to continue product portfolio expansion in the adjacent hospital and biotechnology customer segments.
About Mr. Perez
Mr. Perez has over 30 years of experience in medical device and health care service businesses, serving in a variety of leadership positions. In his role at CaridianBCT, he leads the strategic direction, growth and execution of a global company selling products in more than 90 countries. He also drives the company's mission to improve lives through innovation, quality and services delivered by CaridianBCT's people, products and processes in blood component technologies. Additionally, Mr. Perez serves the Advanced Medical Technology Association (AdvaMed) as a member of the board of directors and its executive committee, as chairman of the Technology and Regulatory Affairs Committee, and as the chairman of the Blood Products and Technology Sector. In addition, he serves as the vice chairman of the board of trustees for the National Blood Foundation (NBF), as a member on the NBF Council on Research and Development, and a board member of both the Foundation for America's Blood Centers® and the Colorado BioScience Association. For more information on CaridianBCT, visit www.caridianbct.com.
About Terumo Corporation
Terumo Corporation is a premier global medical device company with annual sales of more than 3.4 billion dollars for the fiscal year ending March 31, 2010. Founded in 1921, the company develops, manufactures and distributes world-class medical devices , such as syringes, blood bags and IV solutions. Terumo has the biggest share of the world markets for angiography guide wires and perfusion products and is a leading developer of interventional products, such as catheters and stents. For more information, visit www.terumo.com.
(Notice) Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these are forecasts on projections made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.
Lisa Hayes, Vice President of Global Marketing and Corporate Communications
Phone: +1 303.231.4201